BIIB241220C205000
- 0.00
- 0.000.00%
Biogen Newsroom
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Leerink Partners Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $290
BMO Capital Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $164
Biogen's Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles
Biogen's Felzartamab: A Potential Blockbuster in Kidney Treatment With Unique Anti-CD38 Approach
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
BMO Cuts Rating on Merck and Biogen, on Lack of Near Term Catalyst
Biogen Cut to Market Perform From Outperform by BMO Capital
BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164
Biogen Analyst Ratings
PTC Therapeutics Submits NDA for Friedreich Ataxia Treatment Vatiquinone
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Eli Lilly Alzheimer's Therapy Approved in China
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Why Are Biogen, Pfizer, and GSK Trading at a Discount?
Worst Performing Stocks for Tax Loss Selling – Wolfe